key: cord-0978943-9l9kvuk2 authors: Rich, Harvey; Jones, Beth; Hemington-Gorse, Sarah J.; Cubitt, Jonathan J. title: Plastic surgical management of skin cancer patients during the COVID-19 pandemic date: 2020-09-20 journal: J Plast Reconstr Aesthet Surg DOI: 10.1016/j.bjps.2020.08.143 sha: 865db92c4ff94fa1da6e7605eed69000f8bda606 doc_id: 978943 cord_uid: 9l9kvuk2 We present our management of urgent skin cancer referrals during the COVID-19 pandemic through the utilisation of an independent plastic surgery treatment centre (PSTC). During this pandemic, we have seen a worrying decline in the number of new urgent skin cancer referrals being received by our service. However, there are still a number of patients requiring treatment for high risk skin cancers, where delays could potentially lead to significant complications. Our PSTC has allowed us to continue with definitive skin cancer excisions and reconstructions in patients suitable for local anaesthetic day case procedures, with reduced waiting times for the most urgent, protecting other patients and healthcare staff, and minimising the burden on hospital resources. We present our management of urgent skin cancer referrals during the COVID-19 pandemic through the utilisation of an independent plastic surgery treatment centre (PSTC). During this pandemic, we have seen a worrying decline in the number of new urgent skin cancer referrals being received by our service. However, there are still a number of patients requiring treatment for high risk skin cancers, where delays could potentially lead to significant complications. Our PSTC has allowed us to continue with definitive skin cancer excisions and reconstructions in patients suitable for local anaesthetic day case procedures, with reduced waiting times for the most urgent, protecting other patients and healthcare staff, and minimising the burden on hospital resources. Skin cancer, coronavirus, COVID-19, surgery, treatment Dear Editor The first confirmed cases of SARS-CoV-2 cornovirus disease (COVID-19) in the UK were on 29 th January 2020. On 23 rd March, a UK-wide "stay at home" lockdown period commenced, restricting freedom of movement in an effort to mitigate viral spread and protect NHS resources. At the time of writing, the UK has had over 300,000 confirmed cases of COVID-19 with a death toll of over 43,000 people. 1 Many NHS hospitals across the UK are in various stages of lockdown as resources are redirected to the frontline. Anticipating complete redeployment of our department and the inability to operate, we acted early to prioritise urgent skin cancer cases to ensure they were done. 2 We combined all consultant waiting lists to make sure patients were treated in the most timely manner, prioritising Malignant Melanoma (MM) and Squamous Cell Carcinoma (SCC). Our main theatre and peripheral hospital theatre lists were cancelled but we were able to streamline patients through our Plastic Surgical Treatment Centre (PSTC). This opened in September 2019 as a solution to our growing daycase skin cancer patient waiting list. It comprises two operating theatres, a waiting reception area and a recovery bay. Interestingly, during this global pandemic, skin cancer referrals from General Practice and dermatology have reduced as presumably patients were not prepared to present for treatment. Unfortunately, some referrals that were eventually received were of more advanced disease. A proportion are on immunosuppressants or have significant co-morbidities, already shielding in the community, and have been reluctant to attend any skin cancers services based within hospitals. We designed consultant-led virtual clinics for new "urgent suspected cancer" (USC) patients. These patients were asked to submit photogaphs of their lesions to be available for the plastic surgeon when called. This meant patients were consulted very soon after their USC referral was received, often on the same day, and allowed informed discussion and booking of operations all without them having to leave their homes. We encourage all means of MMs. The average waiting times from referral to operation were 138, 51, and 53 days respectively. In March and April, during the peak of the COVID-19 pandemic, we still managed to perform 268 surgical procedures for skin cancers under local anaesthetic through our PSTC service. This comprised 86 urgent BCCs, 100 SCCs and 82 MMs with average waiting times from referral to operation reducing to 95, 39, and 40 days respectively (Figures 1 and 2) . We successfully achieved a 72% caseload during the peak COVID months of March and April with respect to the previous January and February case totals; and there was a 28% overall reduction in mean average waiting times from receipt of referral to date of operation. Trauma patients were also treated through the PSTC when it was available to avoid any theatre slots going unfilled. Whilst we are seeing falling numbers of newly diagnosed urgent skin cancer referrals as anticipated, telemedicine consultation and utilisation of an independent treatment centre for skin cancer surgery has improved service efficiency and the care we deliver to our patients. These adaptations, together with the practical steps in theatre management and minimising footfall, have allowed us to successfully continue working in a COVID -19 world. These are lessons we hope to take forward for the future delivery of our cancer services in the post-COVID era. Funding -none COVID -19 advice for members British Association of Dermatologists & British Society for Dermatological Surgery COVID-19 -Skin cancer surgery guideline. Clinical guidance for the management of skin cancer patients during the coronavirus pandemic